CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 257 enrolled
Drug / intervention
µCordevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03476187
NCT03476187N/ACompleted

Benefits of µCor in Ambulatory Decompensated Heart Failure

Zoll Medical Corporation·interventional·Posted Mar 23, 2018·Updated Jan 8, 2025

In Brief

A clinical study evaluating µCor for Heart Failure. Completed, enrolled 257 participants across 61 sites in 3 countries.

Detailed Summary

Subjects meeting the inclusion/exclusion criteria will wear the µCor for at least 90 days. During the study, clinic follow up will occur every 30 days. For all subjects, each scheduled clinic visit will include assessment of cardiac symptoms and any relevant clinically actionable events. The subject will be given a daily diary to track symptoms, unplanned hospital visits, medication changes, and all other heart failure related clinical events. Weekly phone calls to the subject will be given throughout the duration of the study to remind the patient to use the subject diary and to collect and record heart failure related clinical events. Subjects will be contacted six months and one year from initial enrollment to assess the vital status of the subject, any heart failure related clinical events since the end of µCor wear, and any health care utilization since the end of µCor wear.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesAustria, Germany, United States
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedMar 23, 2018
Enrollment StartAug 17, 2018
Primary CompletionJan 8, 2024
Study CompletionApr 9, 2024
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 8.3 years ago

Interventions

µCordevice

Monitor with µCor